{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:12:02Z","timestamp":1758395522280,"version":"3.44.0"},"reference-count":13,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,6,26]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>Andersen-Tawil syndrome (ATS) is an inherited disorder characterised by the triad of ventricular arrhythmias (VAs), periodic paralysis and dysmorphic features. A 31-year-old woman diagnosed with ATS caused by a <jats:italic>KCNJ2<\/jats:italic> mutation (p.R228ins) was urgently admitted to our hospital following an episode of syncope during exercise. Electrocardiography revealed frequent premature ventricular complexes and non-sustained ventricular tachycardias (VTs) with pleomorphic QRS patterns. During the intravenous flecainide test (30\u2009mg), the frequent VAs were inhibited completely. After oral flecainide (100\u2009mg) was started, VAs, except for a brief bigeminy, were suppressed during the exercise test. On 24-hour Holter recordings, the VAs decreased from 50\u2009133 to 13\u2009363 beats\/day (\u221273%). Sustained VT and syncope were not observed during a 3-year follow-up period. Intravenous flecainide challenge test may be useful in predicting the efficacy of oral flecainide treatment for patients with ATS.<\/jats:p>","DOI":"10.1136\/bcr-2019-229628","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T05:15:14Z","timestamp":1563254114000},"page":"e229628","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Usefulness of the intravenous flecainide challenge test before oral flecainide treatment in a patient with Andersen-Tawil syndrome"],"prefix":"10.1136","volume":"12","author":[{"given":"Akinori","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Chinushi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan"},{"name":"Graduate School of Health Science, Niigata University School of Medicine, Niigata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Minamino","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"2025082723425250000_12.7.e229628.1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut160"},{"key":"2025082723425250000_12.7.e229628.2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200215183"},{"key":"2025082723425250000_12.7.e229628.3","doi-asserted-by":"publisher","DOI":"10.1002\/humu.9483"},{"key":"2025082723425250000_12.7.e229628.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2006.12.031"},{"key":"2025082723425250000_12.7.e229628.5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.hrthm.2014.12.009","article-title":"Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations","volume":"12","author":"Miyamoto","year":"2015","journal-title":"Heart Rhythm"},{"key":"2025082723425250000_12.7.e229628.6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1540-8167.2007.00910.x","article-title":"Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome","volume":"19","author":"Pellizz\u00f3n","year":"2008","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2025082723425250000_12.7.e229628.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.111.962316"},{"key":"2025082723425250000_12.7.e229628.8","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eul188"},{"key":"2025082723425250000_12.7.e229628.9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1942"},{"key":"2025082723425250000_12.7.e229628.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004021107"},{"key":"2025082723425250000_12.7.e229628.11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/clpt.1988.65","article-title":"The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmias","volume":"43","author":"Wang","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"2025082723425250000_12.7.e229628.12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijcard.2018.09.029","article-title":"Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration","volume":"274","author":"Marum","year":"2019","journal-title":"Int J Cardiol"},{"key":"2025082723425250000_12.7.e229628.13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-229628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:43:05Z","timestamp":1756363385000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-229628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,15]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/bcr-2019-229628"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-229628","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}